Aquestive Therapeutics (AQST) Equity Average: 2018-2025
Historic Equity Average for Aquestive Therapeutics (AQST) over the last 7 years, with Sep 2025 value amounting to -$38.3 million.
- Aquestive Therapeutics' Equity Average rose 5.19% to -$38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.3 million, marking a year-over-year increase of 5.19%. This contributed to the annual value of -$83.3 million for FY2024, which is 25.95% up from last year.
- Aquestive Therapeutics' Equity Average amounted to -$38.3 million in Q3 2025, which was up 42.56% from -$66.8 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Equity Average registered a high of -$35.9 million during Q2 2024, and its lowest value of -$113.9 million during Q1 2023.
- Over the past 3 years, Aquestive Therapeutics' median Equity Average value was -$66.8 million (recorded in 2025), while the average stood at -$72.5 million.
- As far as peak fluctuations go, Aquestive Therapeutics' Equity Average crashed by 272.14% in 2021, and later surged by 66.75% in 2024.
- Aquestive Therapeutics' Equity Average (Quarterly) stood at -$71.2 million in 2021, then plummeted by 58.88% to -$113.2 million in 2022, then grew by 7.49% to -$104.7 million in 2023, then spiked by 49.59% to -$52.8 million in 2024, then rose by 5.19% to -$38.3 million in 2025.
- Its Equity Average stands at -$38.3 million for Q3 2025, versus -$66.8 million for Q2 2025 and -$60.5 million for Q1 2025.